Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Graphene brain sensor tested in humans for first time

NCT ID NCT06368310

Knowledge-focused Sponsor: University of Manchester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This study tests a new graphene-based electrode array used during brain tumor surgery to map brain activity. Ten participants will have the device used alongside standard monitoring to check its safety and how well it records brain signals. If awake during surgery, they may do simple tasks to help decode brain signals. The goal is to see if this technology is safe and effective for future use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Graphene Cortical Interface (device)
What this could lead to
If successful, this could pave the way for safer, higher-quality brain mapping during surgery, potentially improving outcomes for brain tumor patients.
What could go wrong
This is a very early, small trial (10 people) focused on safety, not treatment. The device may not work as hoped, and risks include surgical complications or poor signal quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Aug 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Solitary supratentorial tumor radiologically consistent with glioma (intrinsic primary brain tumor) on standard diagnostic MRI; * Planned for surgery under awake conditions or under general anesthesia with intra-operative electrocorticography (ECoG); * English as first language for those subjects with tumors associated with language areas; * Karnofsky performance score \> 70 and World Health Organization (WHO) performance status score ≤ 1; * Willing and able to understand and provide informed consent for participating in the study. Exclusion Criteria: * Contraindications to magnetic resonance imaging (e.g., incompatible implanted devices); * Previous cranial surgery or radiotherapy; * Subjects expected to undergo craniotomy of less than 5 cm in maximum diameter (bone to bone) * Known extracranial malignant neoplasm; * Pregnant or lactating women; * Renal impairment sufficient to limit Gadolinium administration (EGFR \<60 ml/min) * For those subjects with tumors associated with language areas, any contraindication which could preclude them from performing the whole awake intra operative tasks at the discretion of the Investigator (e.g., language function not suitable for monitoring tasks)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumor GLIOMA

Contacts and locations

Locations

  • Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust

    Salford, Greater Manchester, M6 8HD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.